长药控股（300391）被处罚，股民索赔可期

Core Viewpoint - Changjiang Pharmaceutical Holdings Co., Ltd. (*ST Changyao) has been penalized by the China Securities Regulatory Commission (CSRC) for financial misconduct, including false reporting of revenue and profits from 2021 to 2023, which may lead to significant legal and financial repercussions for the company and its investors [2][3][9]. Group 1: Financial Misconduct Details - In November 2020, *ST Changyao acquired 52.75% of Hubei Changjiang Star Pharmaceutical Co., Ltd. and subsequently included it in its financial statements [2][7]. - From 2021 to 2023, the subsidiaries of Changjiang Star fabricated inventory and sales documents, resulting in inflated revenues of CNY 215.32 million, CNY 283.74 million, and CNY 233.63 million, which accounted for 9.12%, 17.57%, and 19.51% of the reported revenues for those years respectively [2][7]. - The inflated profit totals were CNY 56.40 million, CNY 63.38 million, and CNY 43.70 million, representing 35.62%, 88.23%, and 6.42% of the reported profits for the respective years [2][7]. Group 2: Regulatory Actions and Consequences - The CSRC has ordered *ST Changyao to correct its financial statements and has issued warnings along with fines to the company and responsible personnel [2][3]. - The company may face mandatory delisting due to continuous false reporting of financial indicators over three years, as per the Shenzhen Stock Exchange's regulations [3][9]. - Prior to the administrative penalty, *ST Changyao had received a notice of investigation from the CSRC regarding the alleged false reporting of financial data [3][9]. Group 3: Investor Compensation and Legal Actions - A law firm is collecting claims from investors who purchased *ST Changyao's securities between April 28, 2022, and November 6, 2025, and who sold or held their investments after November 7, 2025 [4][9]. - Investors are advised to register for compensation claims, which may include losses from investment differences, commissions, and stamp duties [3][4]. - Required documentation for claims includes identification, securities account information, and transaction records [10].